# A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Source: https://onco.cc/trials/nct06617416/  
OnCo record `nct06617416` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cadonilimab, Sugemalimab in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.

## Summary

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC is a phase 3 interventional study registered as NCT06617416 by Akeso, with 560 participants planned, started 2024-11-12 and due to reach its primary completion in 2026-10-28. Interventions recorded: Cadonilimab (AK104), Sugemalimab. Conditions listed: NSCLC (Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06617416
- Phase: 3
- Setting: A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Consolidation Therapy of AK104 Versus Sugemalimab in Patients With Unresectable Locally Advanced Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent or Sequential Chemoradiotherapy
- Sponsor: Akeso
- Enrolled: 560

## Sources

- ClinicalTrials.gov NCT06617416: https://clinicaltrials.gov/study/NCT06617416

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Sugemalimab](https://onco.cc/drugs/sugemalimab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct06617416.json